GLP-1 weight loss patches reduced cravings during a month-long trial but caused no weight loss and remain unapproved by the FDA.

Terrestrial Bio has dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic ...

Glucagon-like peptide-1 receptor agonists (GLP-1s) have become well known for their significant role as an aid in weight loss ...

Anodyne Nanotech Inc., a clinical-stage biotechnology company simplifying chronic care through transdermal delivery, today ...

VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the ...

Natasha Bhuyan, MD, is a board-certified family physician at Amazon One Medical in Phoenix, AZ, and One Medical’s national medical director and vice president of in-office care. Dr. Bhuyan serves on ...

People searching for an affordable way to lose weight with a GLP-1 drug may come across products marketed as “GLP-1 patches” online. They’re advertised as helping to reduce cravings, control appetite ...

Anodyne Nanotech announced today that it closed a $12.6 million Series A financing to support its transdermal drug delivery technology.

Patches marketed as ‘GLP-1 patches’ actually do not contain GLP-1 active ingredients, such as semaglutide or tirzepatide. Currently, no ‘GLP-1 patches’ are approved by the Food and Drug Administration ...

According to a 2025 Kaiser Family Foundation poll, one in eight adults in the U.S. are currently taking a GLP-1 medication. This number has probably increased even more since the poll was conducted, ...